3 ways digital technology can help drug makers fight COVID-19

An employee works inside a laboratory at Piramal's Research Centre in Mumbai August 11, 2014. Indian drugmakers are fleeing a regulatory morass at home and moving some research and development to Europe and the United States as they try to boost margins by producing high-value drugs. Companies like Piramal Enterprises Ltd, Sun Pharmaceutical Industries Ltd and Lupin Ltd are investing millions of dollars and placing their future growth in foreign regulators' hands, as they seek to add more complex drugs to their product lines. Picture taken August 11, 2014. To match INDIA-PHARMACEUTICALS/RESEARCH/ REUTERS/Danish Siddiqui (INDIA - Tags: HEALTH BUSINESS DRUGS SOCIETY SCIENCE TECHNOLOGY) - GM1EA8T0EJC01

Drug makers are crucial in the fight against COVID-19 - but their own supplies have been disrupted. Image: REUTERS/Danish Siddiqui

Karishma Banga
Research Fellow, Overseas Development Institute (ODI)
Our Impact
The Big Picture
Explore and monitor how COVID-19 is affecting economies, industries and global issues
A hand holding a looking glass by a lake
Crowdsource Innovation
Get involved with our crowdsourced digital platform to deliver impact at scale
Stay up to date:


Have you read?
Export intensity in Indian pharma firms in the global value chain (%). Digital capability index is constructed using principal component analysis on the share of software, technology, and communication assets in total sales of the firm. Digital leaders are those firms in which digital capability index is above the median value of the industry, while digital followers are those with digital capability index below the median value. Panel covers 2001-2015. Average values are statistically significantly different at 1%. Image: Prowess
Share in global pharmaceutical patents. Image: Prowess
R&D intensity in Indian pharma firms in the global value chain. Panel covers 2001-2015. The average values are statistically significantly different at 1%. Image: Prowess
Product sophistication index in Indian pharma firms in the global value chain. Image: Prowess

What is the World Economic Forum doing to manage emerging risks from COVID-19?

Don't miss any update on this topic

Create a free account and access your personalized content collection with our latest publications and analyses.

Sign up for free

License and Republishing

World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.

The views expressed in this article are those of the author alone and not the World Economic Forum.

Related topics:
COVID-19Advanced ManufacturingChemical and Advanced MaterialsGlobal HealthIndiaEmerging TechnologiesArtificial IntelligenceThe Digital Transformation of BusinessThe Digital EconomySupply ChainsHealth and Healthcare
World Economic Forum logo
Global Agenda

The Agenda Weekly

A weekly update of the most important issues driving the global agenda

Subscribe today

You can unsubscribe at any time using the link in our emails. For more details, review our privacy policy.

Here’s what to know about the new COVID-19 Pirola variant

Lora du Moulin and Charlotte Edmond

October 11, 2023

About Us



Partners & Members

  • Join Us

Language Editions

Privacy Policy & Terms of Service

© 2023 World Economic Forum